rais guidanc due pharmedium op perform suggest macro
environ remain solid remain posit given continu strength pharma
exhibit specialti volum growth outpac broader market given
lead posit specialti ion gpo think benefit biosimilar adopt
particularli interchang
despit make progress last year toward resum oper optim
busi management decid exit pharmedium due consider challeng face
move busi forward given regulatori challeng oper issu inabl
make suffici progress remedi along financi burden continu
oper given state busi enter sale process
said due exit expect realiz cash tax benefit
expect realiz ratabl management also expect impair major
remain pharmedium intang asset remain
intang asset
rais adj ep guidanc due strong
perform share repurchas exit pharmedium busi management note
pharmedium exit repres slightli less half upward guidanc
revis estim lower share guidanc due opportunist share buyback
repres impli remain guidanc revis
repres improv oper perform result pharmedium exit
face tailwind pharmedium oper loss
realiz loss
although provid formal quarterli guidanc management note expect
adj ep growth come toward low end full year growth rang
impli rang consensu deceler y/
adj ep growth rel due benefit relat posit gener
administr expens item realiz expect
rais adj ep estim
respect also rais price target base revis dcf analysi
impli share trade adj ep estim
current level
pleas see page report import disclosur
posit believ share trade attract multipl particularli
fundament core pharmaceut distribut stabil show
sign improv also well posit growth rel peer given
align anchor custom grow market rate addit
view lead posit specialti favor prove particularli benefici
signific biosimilar adopt
resolut opioid litig
top-lin growth driven specialti
esrx onboard ci
gross margin
ebit margin
digit due greater expect
growth specialti
gross margin approach due
better expect mix gener
sg better expect due
share come lower due greater
expect share repo
top-lin growth toward low-singl
digit due slower expect
growth specialti
margin closer due higher
sg come wors expect
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
million except per-shar data
cowen compani
changevariancetot cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig net incom deal-rel incom ex-discontinu average ep ex-discontinu distributiontot chang basi earn basi servicesoth chang basi earn basi cowen
million except per-shar data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig own net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani report cowen compani
asset receiv net doubt recov expens current charg total liabil account payabl current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani report cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net incom provis loss account provis defer incom employe stock loss dispos properti equipment- impair charg equiti investment- lifo pension settlement- includ intang asset loss earli retir chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash proce sale properti equipment- equiti proce sale business- purchas invest secur avail sale- net cash provid use invest activ continu net cash provid use invest activ discontinu ops- net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri payment premium earli retir debt- defer financ cost other- exercis warrants- exercis stock dividend common purchas cap call net cash provid use financ activ continu net cash provid use financ activ discontinu op net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number risk associ pt includ lower expect brand
inflat higher expect brand inflat loss signific custom
higher expect litig expens and/or settlement relat opioid
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
